RBC Capital raised the firm’s price target on Ideaya Biosciences (IDYA) to $45 from $41 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Multiple Shots on Goal in High-Unmet-Need Oncology: IDEAYA’s Diversified Pipeline and Strong Funding Underpin Buy Rating
- IDEAYA updates precision oncology strategy at JPM 2026
- IDEAYA sets 2026 objectives to advance registrational trials
- Ideaya Biosciences provides business update for 2026
- Ideaya Biosciences assumed with a Buy at UBS